LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells
Authors:
Open Access
- 23 December 2021
- journal article
- research article
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 54 (2) , 261-270
Abstract
Hepatocellular carcinoma (HCC) is one of the most malignant tumors worldwide and HCC patients often develop drug resisitene. Long non-coding RNAs (LncRNAs) are closely related to cell cycle, growth, development, differentiation, and apoptosis. Abnormally expressed lncRNAs have been proved to mediate drug resistance in tumor cells. However, the effect of LIMT on drug resistance has not been explored in HCC. In this study, we explored the effect of long non-coding RNA LIMT on drug resistance and its underlying mechanism in hepatocellular carcinoma (HCC). Our results showed that LncRNA LINC01089 (LIMT) expression is downregulated in 78.57% (44/56) of 56 HCC tumor tissue samples. LIMT expression is also downregulated in HCC cells compared with that in normal liver LO2 cells. Inhibition of LIMT increases the resistance to sorafenib and promotes cell invasion via regulation of epithelial to mesenchymal transition (EMT) in HCC. StarBase V3.0 was used to predict the potential binding site of miR-665 in LIMT. Furthermore, miR-665 participates in sorafenib resistance and also regulates the level of EMT-related proteins in HCC cells. A rescue experiment demonstrated that silencing of LIMT eliminats the inhibitory effect of the miR-665 inhibitor on sorafenib resistance in HCC cells. Taken together, our findings revealed that downregulation of LIMT increases the resistance of HCC to sorafenib via miR-665 and EMT. Therefore, LIMT, which serves as a therapeutically effective target, will provide new hope for the treatment of HCC.Keywords
This publication has 42 references indexed in Scilit:
- Silencing of LncRNA-HOTAIR decreases drug resistance of Non-Small Cell Lung Cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1Biochemical and Biophysical Research Communications, 2018
- Epithelial Mesenchymal Transition in Tumor MetastasisAnnual Review of Pathology: Mechanisms of Disease, 2018
- BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinomaCancer Letters, 2017
- Exosomal miR-665 as a novel minimally invasive biomarker for hepatocellular carcinoma diagnosis and prognosisOncotarget, 2017
- FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancerMolecular Cancer, 2017
- In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3–Mediated ApoptosisClinical Cancer Research, 2017
- Sorafenib: A Review in Hepatocellular CarcinomaTargeted Oncology, 2017
- Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancerJournal of Experimental & Clinical Cancer Research, 2017
- LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancerEMBO Molecular Medicine, 2016
- Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in CancerMolecules, 2016